LUND, Sweden, April 17, 2026 (GLOBE NEWSWIRE) -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announces that it ...
A newly proposed model suggests cancer cells may resist treatment not just through genetic mutations, but by dynamically ...
Gram-stained section of a macrophage with ingested S epidermidis bacteria, seen as purple granules within its cytoplasm. In this stain, the nucleus appears pale, with a reddish nucleolus. It is ...
Scientists at the MRC Laboratory of Medical Sciences (LMS) have discovered a DNA-based “dimmer switch” that regulates the activity of a critical developmental gene, Cdx2. This work could pave the way ...
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced positive data from its HT-VA study, conducted under its Cooperative Research and Development ...
CGTE researchers Dr. Stelios Andreadis, center director, and Dr. Kirk Personius are lead co-authors of a paper in the October 24th edition of Nature Communications. This study describes experiments ...
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that ...
The field of plant epigenetics is increasingly recognized for its crucial role in mediating plant responses to diverse environmental stressors intensified ...
Yuancheng Ryan Lu could barely breathe while he waited for his labmate to adjust the microscope focus. On the slide in front ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results